Lauflumide is the common alternative of modafinil. Modafinil is commonly prescribed for the research narcolepsy.
(S)-Sunvozertinib ((S)-DZD9008) is the S-enantiomer of Sunvozertinib, EGFR exon 20 NPH and ASV insertion, EGFR L858R/T790M mutation and Her2 exon 20 YVMA insertion (IC50 was 51.2 nM, 51.9 nM, 1 nM and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK.
SB-705498 is a potent, selective and orally bioavailable transient receptor potential vanilloid 1 (TRPV1) receptor antagonist with a pIC50 of 7.1.
SAR-20347 is a potent dual inhibitor of JAK1 and TYK2 with IC50 values of 23 and 0.6 nM, respectively.
Pevonedistat (MLN4924) is a first-of-its-kind (first-in-class) small molecule inhibitor of Nedd8 activating enzyme (NAE) with an IC50 of 4.7 nM.
DSR-6434 is a potent and selective Toll-like receptor 7 (TLR7) agonist for both humans and mice with TLR7 EC50 7.2 nM and 4.6 nM, respectively. DSR-6434 has a strong antitumor effect.
Stavudine (D4T) is a potent inhibitor of HIV-1 reverse transcriptase in vitro. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis.
Pralsetinib (BLU-667) is a next generation highly potent, selective RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion.
Sophocarpine is a HERG K+ channel blocker with IC50 of 100-300 μM and Na+ channel inward current inhibitor.
Ciproxifan is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes.